Original Article

You have full text access to this OnlineOpen article

NAFLD may be a common underlying liver disease in patients with hepatocellular Carcinoma in the United States

  1. Jorge A. Marrero M.D.*,
  2. Robert J. Fontana,
  3. Grace L. Su,
  4. Hari S. Conjeevaram,
  5. Dawn M. Emick,
  6. Anna S. Lok

Article first published online: 7 MAR 2007

DOI: 10.1002/hep.1840360609

Issue

Hepatology

Hepatology

Volume 36, Issue 6, pages 1349–1354, December 2002

Additional Information

How to Cite

Marrero, J. A., Fontana, R. J., Su, G. L., Conjeevaram, H. S., Emick, D. M. and Lok, A. S. (2002), NAFLD may be a common underlying liver disease in patients with hepatocellular Carcinoma in the United States. Hepatology, 36: 1349–1354. doi: 10.1002/hep.1840360609

Author Information

  1. Department of Internal Medicine, Division of Gastroenterology, University of Michigan, Ann Arbor, MI

*University of Michigan, 3912 Taubman Center, Ann Arbor, MI 48109-0362.: fax: 734-936-7392

Publication History

  1. Issue published online: 7 MAR 2007
  2. Article first published online: 7 MAR 2007
  3. Manuscript Accepted: 1 SEP 2002
  4. Manuscript Received: 18 FEB 2002

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (576K)

Reference

  • 1
    Howe HL, Wingo PA, Thun MJ, Ries LAG, Rosenberg HM, Feigal EG, Edwards BK. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst 2001; 93: 824–842.
  • 2
    El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745–750.
  • 3
    Diehl AM. Nonalcoholic steatohepatitis. Semin Liver Dis 1999; 19: 221–229.
  • 4
    Powell EE, Cooksley GE, Hanson R, Searle J, Halliday JW, Powell LW. Natural history of nonalcoholic steatohepatitis: a follow-up study of 42 patients followed for up to 21 years. Hepatology 1990; 11: 74–80.
    Direct Link:
  • 5
    Bacon B, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107: 1103–1106.
  • 6
    Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413–1419.
  • 7
    Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29: 664–669.
    Direct Link:
  • 8
    Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 2000; 32: 689–692.
    Direct Link:
  • 9
    Ong J, Younossi ZM, Reddy V, Price LL, Gramlich T, Mayes J, Boparai N. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver. Liver Transpl 2001; 7: 797–801.
    Direct Link:
  • 10
    Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134–140.
  • 11
    El-Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology 2001; 33: 62–65.
    Direct Link:
  • 12
    Oka H, Kurioka N, Kim K. Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology 1990; 12: 680–687.
    Direct Link:
  • 13
    Colombo M, De Franchis R, Del Ninno E. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991; 325: 675–680.
  • 14
    Pateron D, Ganne-Carrie N, Trinchet JC. Prospective study of screening of hepatocellular carcinoma in caucasian patients with cirrhosis. J Hepatol 1994; 20: 65–71.
  • 15
    Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, Piscaglia F, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001; 48: 251–259.
  • 16
    Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso MC, Sala M, Bru C, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999; 29: 62–67.
    Direct Link:
  • 17
    Alberti KG, Zimmet PZ. Definition, diagnosis, classification of diabetes mellitus, and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med 1998; 15: 539–553.
    Direct Link:
  • 18
    Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, et al. Liver transplantation for treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693–699.
  • 19
    Brunt EM. Non-alcoholic steatohepatitis: definitions and pathology. Semin Liver Dis 2001; 21: 3–16.
  • 20
    Younossi ZM, Gramlich T, Liu YC, Matteoni C, Petrelli M, Goldblum J, Rybicki L, et al. Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod Pathol 1998; 11: 560–565.
  • 21
    Zen Y, Katayanagi K, Tsuneyama K, Harada K, Araki I, Nakanuma Y. Hepatocellular carcinoma arising in non-alcoholic steatohepatitis. Pathol Int 2001; 51: 127–131.
    Direct Link:
  • 22
    Agarwal SR, Malhotra V, Sakhuja P, Sarin SK. Clinical, biochemical and histological profile of nonalcoholic steatohepatitis. Indian J Gastroenterol 2001; 20: 183–186.
  • 23
    Yang HY, Lu SN, Liaw YF, You SL, Sun CS, Wang LY, Hsiao CK, et al. Hepatitis B antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168–174.
  • 24
    Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology 1997; 26 (Suppl): 34S.
    Direct Link:
  • 25
    Yuen MF, Cheng CC, Lauder IJ, Lam SK, Gaik-Cheng C, Lai CL. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000; 31: 330–335.
    Direct Link:
  • 26
    Llovet JM, Bruix J. Early diagnosis and treatment of hepatocellular carcinoma. Baillieres Clin Gastroenterol 2000; 14: 991–1008.
  • 27
    Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology 1998; 27: 273–278.
    Direct Link:
  • 28
    Marrero JA, Gosh M, Nour K, Su GL, Fontana RJ, Conjeevaram HS, Lok AS. Des-γ carboxy prothrombin is a more sensitive and reliable marker for hepatocellular carcinoma than α-fetoprotein in american patients [Abstract]. Hepatology 2001; 34 (Part 2): 14A.
Get PDF (576K)